STXI aims to replicate the performance of an index comprised of a small selection of global stocks. The ETF achieves this by investing in the constituent companies of the underlying index, weighting them according to their index representation. With only 10项持仓, STXI offers a concentrated approach to global equities, potentially leading to higher volatility compared to more diversified ETFs. The fund's top holdings include ASML Holding NV (2.94%), Novartis AG Registered Shares (1.77%), and Roche Holding AG (1.77%). Other significant allocations include HSBC Holdings PLC (1.71%) and AstraZeneca PLC (1.67%). This concentrated portfolio may appeal to investors seeking targeted exposure to specific global companies rather than broad market diversification. STXI's strategy is suited for investors with a higher risk tolerance seeking concentrated exposure.
STXI (STXI) ETF Analysis
STXI is an index-tracking ETF providing exposure to a basket of global stocks. With holdings in just 10 companies, it offers a concentrated portfolio. The fund's top allocations include ASML Holding NV, Novartis AG, and Roche Holding AG. As of 2026-03-15, STXI exhibits a dividend yield of 0.00% and a three-year beta of 0.00, indicating low volatility relative to the broader market. Past performance does not guarantee future results.
STXI (STXI) ETF — Price, Holdings & Analysis
STXI is an index-tracking ETF providing exposure to a basket of global stocks. With holdings in just 10 companies, it offers a concentrated portfolio. The fund's top allocations include ASML Holding NV, Novartis AG, and Roche Holding AG. As of 2026-03-15, STXI exhibits a dividend yield of 0.00% and a three-year beta of 0.00, indicating low volatility relative to the broader market. Past performance does not guarantee future results.
ETF Overview
Risk Metrics
STXI's concentrated portfolio of only 10项持仓 presents a significant concentration risk. A downturn in any of its top holdings, such as ASML Holding NV, Novartis AG, or Roche Holding AG, could disproportionately impact the ETF's performance. The ETF's three-year beta of 0.00 suggests it has historically exhibited very low volatility relative to the market. However, this may not hold true in all market conditions, especially given the concentrated nature of its holdings. Investors should carefully consider their risk tolerance and investment objectives before investing in STXI, acknowledging the potential for amplified volatility due to its concentrated nature. Past performance does not guarantee future results.
Top Holdings
- ASML Holding NV (ASML.AS): 2.94%
- Novartis AG Registered Shares (NOVN.SW): 1.77%
- Roche Holding AG (ROG.SW): 1.77%
- HSBC Holdings PLC (HSBA.L): 1.71%
- AstraZeneca PLC (AZN.L): 1.67%
- Nestle SA (NESN.SW): 1.49%
- Toyota Motor Corp (7203.T): 1.33%
- Shell PLC (SHEL.L): 1.26%
- Siemens AG (SIE.DE): 1.20%
- Royal Bank of Canada (RY): 1.18%
Dividend Yield
0.00%
Risk Metrics
- Beta: 0.00
常见问题
What is STXI and what does it track?
STXI is an exchange-traded fund (ETF) designed to track the performance of a specific index composed of a small selection of global stocks. The ETF provides investors with a way to gain exposure to these companies through a single investment vehicle. As of 2026-03-15, STXI holds only 10 companies, with top allocations including ASML Holding NV, Novartis AG, and Roche Holding AG. The fund's concentrated nature means its performance is heavily influenced by the performance of these key holdings. Investors should be aware of this concentration risk before investing.
What is the expense ratio for STXI?
The expense ratio for STXI is not provided in the available data. Without this information, it is impossible to compare STXI's cost to similar ETFs or the category average. Investors should consult the fund's official documentation to determine the exact expense ratio before investing. This fee is crucial for understanding the long-term cost of owning the ETF, as it directly impacts returns.
What are the top holdings in STXI?
As of 2026-03-15, the top five holdings in STXI are: 1) ASML Holding NV (ASML.AS) at 2.94%, 2) Novartis AG Registered Shares (NOVN.SW) at 1.77%, 3) Roche Holding AG (ROG.SW) at 1.77%, 4) HSBC Holdings PLC (HSBA.L) at 1.71%, and 5) AstraZeneca PLC (AZN.L) at 1.67%. These five companies represent a significant portion of the ETF's total assets, highlighting the fund's concentrated nature. The performance of these companies will have a substantial impact on the overall performance of STXI.
Is STXI a good long-term investment?
Whether STXI is a suitable long-term investment depends on an investor's individual circumstances, risk tolerance, and investment objectives. The ETF's concentrated portfolio of just 10项持仓 may lead to higher volatility compared to more diversified options. As of 2026-03-15, STXI has a dividend yield of 0.00% and a three-year beta of 0.00. Investors should carefully consider these factors and conduct thorough research before making any investment decisions. Past performance does not guarantee future results.
How does STXI compare to similar ETFs?
Without specific data on comparable ETFs, a direct comparison is challenging. However, STXI's defining characteristic is its highly concentrated portfolio of only 10项持仓. Many similar ETFs tracking global equities will hold a much larger number of companies, providing greater diversification. Investors should compare STXI's expense ratio (not available in provided data), AUM, and investment strategy to those of other global equity ETFs to determine which fund best aligns with their needs. The level of concentration is a key differentiator.
Does STXI pay dividends?
As of 2026-03-15, STXI exhibits a dividend yield of 0.00%. This indicates that the ETF is not currently distributing any dividend income to its shareholders. Investors seeking dividend income may want to consider alternative ETFs with a higher dividend yield. However, dividend yield is only one factor to consider when evaluating an ETF's overall suitability.